文献速递细菌感染、耐药与抗菌药物

抗生素创新融资拉动机制:欧洲的机遇

Financing Pull Mechanisms for Antibiotic-Related Innovation: Opportunities for Europe.
PubMed 文献 · Clin Infect Dis · 2020-01-01

抗生素创新因企业缺乏盈利能力而面临严重危机,小公司难以靠收入覆盖运营成本。本文从欧洲视角审视四种潜在融资模型:诊断相关组豁免、管理税、可转让排他性凭证和欧洲「付费或参与」模型,其吸引力与各国测试意愿正通过EU-JAMRAI评估。

要点

  • 抗生素创新因缺乏盈利能力面临危机,小公司难以存活。
  • 四种融资模型:DRG豁免、管理税、可转让排他性凭证、「付费或参与」。
  • 模型吸引力与各国测试意愿正通过EU-JAMRAI评估。

核心结论

  • 抗生素创新面临危机,需关注激励措施的融资方式而非仅激励本身。
  • 四种融资模型正通过EU-JAMRAI评估其吸引力与各国测试意愿。

研究设计与样本

  • 本文为观点/综述类文章,从欧洲视角审视四种抗生素创新融资模型。

主要发现

  • 公司因缺乏盈利能力持续退出抗生素市场。
  • 新抗生素须谨慎使用以减缓耐药传播,但小公司无法靠不覆盖运营成本的收入存活。
  • 公司破产或转向其他治疗领域后,患者可能无法获得这些抗生素。
  • 已有大量研究详述刺激抗生素创新的激励措施,但对其融资关注甚少。

关键数值与推荐

  • 四种融资模型:诊断相关组豁免、管理税、可转让排他性凭证、欧洲「付费或参与」模型。

临床怎么用

  • 临床医生应了解抗生素创新融资机制对可持续供应和合理使用的影响。

局限性

  • 原文未报告具体数据、样本量或统计检验结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Antibiotic innovation is in serious jeopardy as companies continue to abandon the market due to a lack of profitability. Novel antibiotics must be used sparingly to hinder the spread of resistance, but small companies cannot survive on revenues that do not cover operational costs. When these companies either go bankrupt or move onto other therapeutic areas, these antibiotics may be no longer accessible to patients. Although significant research efforts have detailed incentives to stimulate antibiotic innovation, little attention has been paid to the financing of these incentives. In this article, we take a closer look at 4 potential financing models (diagnosis-related group carve-out, stewardship taxes, transferable exclusivity voucher, and a European-based "pay or play" model) and evaluate them from a European perspective. The attractiveness of these models and the willingness for countries to test them are currently being vetted through the European Joint Action on AMR and Healthcare-Associated Infections (EU-JAMRAI).

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Årdal C, Lacotte Y, Ploy MC, et al. Financing Pull Mechanisms for Antibiotic-Related Innovation: Opportunities for Europe. Clin Infect Dis. 2020. PMID: 32060511. doi:10.1093/cid/ciaa153

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。